GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chimerix Inc (NAS:CMRX) » Definitions » Cyclically Adjusted PB Ratio

Chimerix (Chimerix) Cyclically Adjusted PB Ratio : 0.20 (As of Apr. 27, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Chimerix Cyclically Adjusted PB Ratio?

As of today (2024-04-27), Chimerix's current share price is $0.8999. Chimerix's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was $4.58. Chimerix's Cyclically Adjusted PB Ratio for today is 0.20.

The historical rank and industry rank for Chimerix's Cyclically Adjusted PB Ratio or its related term are showing as below:

CMRX' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.19   Med: 0.43   Max: 2.2
Current: 0.19

During the past years, Chimerix's highest Cyclically Adjusted PB Ratio was 2.20. The lowest was 0.19. And the median was 0.43.

CMRX's Cyclically Adjusted PB Ratio is ranked better than
82.81% of 640 companies
in the Biotechnology industry
Industry Median: 1.715 vs CMRX: 0.19

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Chimerix's adjusted book value per share data for the three months ended in Dec. 2023 was $2.171. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $4.58 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Chimerix Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Chimerix's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chimerix Cyclically Adjusted PB Ratio Chart

Chimerix Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 1.55 0.42 0.21

Chimerix Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.42 0.27 0.26 0.21 0.21

Competitive Comparison of Chimerix's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Chimerix's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chimerix's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chimerix's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Chimerix's Cyclically Adjusted PB Ratio falls into.



Chimerix Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Chimerix's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=0.8999/4.58
=0.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chimerix's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Chimerix's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book=Book Value per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=2.171/129.4194*129.4194
=2.171

Current CPI (Dec. 2023) = 129.4194.

Chimerix Quarterly Data

Book Value per Share CPI Adj_Book
201403 3.328 99.695 4.320
201406 5.386 100.560 6.932
201409 4.850 100.428 6.250
201412 6.693 99.070 8.743
201503 6.234 99.621 8.099
201506 8.710 100.684 11.196
201509 8.023 100.392 10.343
201512 7.267 99.792 9.424
201603 6.788 100.470 8.744
201606 6.491 101.688 8.261
201609 6.204 101.861 7.882
201612 5.937 101.863 7.543
201703 5.646 102.862 7.104
201706 5.307 103.349 6.646
201709 5.027 104.136 6.248
201712 4.669 104.011 5.810
201803 4.307 105.290 5.294
201806 3.999 106.317 4.868
201809 3.736 106.507 4.540
201812 3.501 105.998 4.275
201903 3.220 107.251 3.886
201906 2.911 108.070 3.486
201909 1.824 108.329 2.179
201912 1.785 108.420 2.131
202003 1.632 108.902 1.939
202006 1.498 108.767 1.782
202009 1.328 109.815 1.565
202012 1.168 109.897 1.375
202103 1.550 111.754 1.795
202106 1.381 114.631 1.559
202109 1.204 115.734 1.346
202112 0.786 117.630 0.865
202203 0.547 121.301 0.584
202206 0.319 125.017 0.330
202209 3.111 125.227 3.215
202212 2.917 125.222 3.015
202303 2.713 127.348 2.757
202306 2.530 128.729 2.544
202309 2.343 129.860 2.335
202312 2.171 129.419 2.171

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Chimerix  (NAS:CMRX) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Chimerix Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Chimerix's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Chimerix (Chimerix) Business Description

Industry
Traded in Other Exchanges
Address
2505 Meridian Parkway, Suite 100, Durham, NC, USA, 27713
Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through license agreements and a federal contract with the U.S. Biomedical Advanced Research and Development Authority (BARDA) for research and advanced development of drugs to treat various human diseases. The company operates only in one business segment namely pharmaceuticals.
Executives
Fred A Middleton director 400 SOUTH EL CAMINO REAL STE 1200, SAN MATEO CA 94402-1708
David Jakeman officer: Principal Accounting Officer C/O CHIMERIX, INC.,, 2505 MERIDIAN PARKWAY, SUITE 100, DURHAM NC 27713
Michael A. Sherman director, officer: Chief Executive Officer 3000 KENT AVE STE A1-100, WEST LAFAYETTE IN 47906
Martha J Demski director 7770 REGENTS ROAD SUITE 113-505, SAN DIEGO CA 92122
Robert J. Meyer director 2505 MERIDIAN PARKWAY, C/O CHIMERIX, INC, SUITE 100, DURHAM NC 27713
Michael T. Andriole officer: Chief Business Officer C/O ENDOCYTE, INC., 3000 KENT AVENUE, SUITE A1-100, WEST LAFAYETTE IN 47906
Cantex Pharmaceuticals, Inc. 10 percent owner 1792 BELL TOWER LANE, SUITE 222, WESTON FL 33326
Victoria Vakiener director C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Allen S. Melemed officer: Chief Medical Officer C/O CHIMERIX, INC., 2505 MERIDIAN PARKWAY, SUITE 100, DURHAM NC 27713
Pratik S Multani director C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO CA 92121
William Garrett Nichols officer: Chief Medical Officer C/O CANDEL THERAPEUTICS, INC., 117 KENDRICK ST SUITE 450, NEEDHAM MA 02494
Michael Albert Alrutz officer: Principal Executive Officer 2530 MERIDIAN PARKWAY, 2ND FLOOR, DURHAM NC 27713
M Michelle Berrey officer: Chief Medical Officer 303A COLLEGE ROAD EAST, PRINCETON NJ 08450
Ernest Mario director 20 FAIRMOUNT AVENUE, P.O. BOX 445, CHATHAM NJ 07928
Ed Greissing director 2505 MERIDIAN PARKWAY, C/O CHIMERIX, INC, SUITE 100, DURHAM NC 27713